Phibro Animal Health (PAHC) Fundamental Analysis: Revenue, Earnings & Valuation

8.35 / 10

Outperform

Fundamentally, PAHC is rated Outperform with an 8.3/10 score. Key strengths include PB‑ROE and Cash‑MV, while Cash‑UP and operating cash flow lag. The composite fund score of 8.35 underscores robust valuation metrics, supporting a positive outlook.

Analysis Checks(7/10)

Revenue-MV

Value1.22

Score0/3

Weight-13.06%

1M Return-6.46%

Net cash flow from operating activities per share (YoY growth rate %)

Value-8.60

Score2/3

Weight6.23%

1M Return2.28%

PB-ROE

Value-0.53

Score2/3

Weight2.35%

1M Return0.81%

Basic earnings per share (YoY growth rate %)

Value1883.33

Score3/3

Weight14.47%

1M Return4.72%

Total profit (YoY growth rate %)

Value522.87

Score3/3

Weight15.58%

1M Return5.14%

Net cash flow from operating activities (YoY growth rate %)

Value-8.53

Score1/3

Weight2.68%

1M Return1.00%

Cash-UP

Value-0.98

Score1/3

Weight1.81%

1M Return0.66%

Diluted earnings per share (YoY growth rate %)

Value1883.33

Score3/3

Weight15.36%

1M Return5.00%

Asset-MV

Value-0.55

Score3/3

Weight32.03%

1M Return9.13%

Cash-MV

Value-0.21

Score3/3

Weight22.55%

1M Return6.61%

Is PAHC undervalued or overvalued?

PAHC scores 8.35/10 on fundamentals and holds a Discounted valuation at present. Backed by its 17.47% ROE, 6.29% net margin, 23.72 P/E ratio, 6.57 P/B ratio, and 372.92% earnings growth, these metrics solidify its Outperform investment rating.